Biologics Contract Development Market, By Service Type (Contract Research, Contract Manufacturing, and Contract Testing), By Biologics Type, By End-User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
REPORT HIGHLIGHT
Biologics Contract Development Market size was valued at US$ 7,509.65 Million in 2024, expanding at a CAGR of 8.94% from 2025 to 2032.
The biologics contract development market refers to the industry where companies outsource the development and manufacturing of biologic drugs to specialized service providers. Biologics are complex products derived from living organisms, including monoclonal antibodies, vaccines, and gene therapies. Contract development organizations (CDOs) provide a range of services, from early-stage research and process development to clinical trials and large-scale manufacturing. These partnerships enable biopharma companies to reduce costs, enhance efficiency, and access specialized expertise. As the demand for biologics grows, fueled by advancements in personalized medicine and treatments for rare diseases, the biologics contract development market continues to expand. Companies in this space are focusing on regulatory compliance, innovation, and cost-effective solutions to meet the evolving needs of the industry.
Biologics Contract Development Market- Market Dynamics
Rising Demand for Personalized Medicine Driving Biologics Contract Development Growth
The growing demand for personalized medicine is a key driver of the biologics contract development market. Personalized medicine tailors treatments to an individual\'s genetic profile, enhancing treatment efficacy and minimizing adverse effects. According to the U.S. National Institutes of Health (NIH), the global market for personalized medicine is expected to reach $3.5 trillion by 2025.
As biologic therapies are essential to personalized medicine, the demand for specialized contract development services continues to rise. The increasing prevalence of genetic disorders and cancer further boosts the need for biologics. The NIH estimates that approximately 1 in 10 people worldwide are living with a rare disease, many of whom require biological treatments. These factors have led biopharma companies to increasingly partner with contract development organizations (CDOs) to access the necessary expertise and efficiently scale production.
Biologics Contract Development Market- Segmentation Analysis:
The Global Biologics Contract Development Market is segmented based on Service Type, Biologics Type, End-User, and Region.
By Service Type
The biologics contract development market is divided into three categories based on service type: Contract Research, Contract Manufacturing, and Contract Testing. The Contract Manufacturing segment is the largest and has experienced substantial growth due to the increasing demand for large-scale production of biological drugs, including monoclonal antibodies and vaccines. Contract manufacturing organizations (CMOs) provide biopharma companies with the expertise, facilities, and equipment necessary for efficient biologics production while ensuring regulatory compliance. Since biologic therapies require specialized processes, such as cell culture and fermentation, outsourcing these services helps companies reduce costs and accelerate time-to-market. The growing demand for scalable manufacturing solutions, particularly driven by personalized medicine and biologic treatments for complex diseases, has solidified the importance of this segment. According to the U.S. Food and Drug Administration (FDA), the number of biologic drug approvals has been rising steadily, with over 50 biologic drug approvals each year in recent years. The FDA\'s approval of biologics is creating a greater demand for contract manufacturing services, as biopharma companies seek partners to scale production and meet market needs.
By Biologics Type
The market is also segmented into four categories based on biologics type: Monoclonal Antibodies, Vaccines, Gene Therapies, and Recombinant Proteins. Monoclonal Antibodies (mAbs) is the most dominant segment, driven by the increasing demand for mAbs in the treatment of various conditions, such as cancer, autoimmune disorders, and infectious diseases. mAbs are highly specific, offering targeted therapies that provide better efficacy and fewer side effects compared to traditional drugs. The continued advancements in biotechnology have led to the development of new mAbs, further increasing their use in personalized medicine. According to the National Institutes of Health (NIH), monoclonal antibodies represent a significant portion of the biologics pipeline, with several high-profile mAbs approved for the treatment of cancer, rheumatoid arthritis, and other chronic diseases. The NIH estimates that the global market for monoclonal antibodies will exceed $200 billion by 2025, reflecting the growing demand for these therapies and the corresponding rise in need for contract development services related to mAb production.
Governments worldwide are investing in biologics and personalized medicine, with initiatives like the U.S. National Cancer Institute\'s (NCI) Cancer Moonshot initiative and EU Horizon 2020 funding driving innovation and research in biologics, including monoclonal antibodies. These investments contribute to market growth, reinforcing the importance of mAb-focused contract development organizations (CDOs) in the biologics sector.
Biologics Contract Development Market- Geographical Insights
North America holds a significant share of the biologics contract development market, driven by its robust healthcare infrastructure, advanced research capabilities, and high demand for biologic therapies. The U.S. Food and Drug Administration (FDA) plays a critical role in regulating biologics, ensuring the safety and efficacy of treatments, which boosts confidence in the market. The region is home to leading biopharma companies, academic institutions, and contract development organizations (CDOs), establishing it as a key hub for biologics development.
The U.S. has a high prevalence of chronic diseases, including cancer, diabetes, and autoimmune disorders, further accelerating the demand for biologic treatments. Additionally, the region\'s healthcare policies encourage innovation and reimbursement for personalized medicine, attracting significant investments in biologics. The increasing trend of outsourcing biologic manufacturing and development services to specialized CDOs also contributes to the market\'s growth. With ongoing advancements in genomics and biotechnology, North America is well-positioned to continue leading in biologics development and contract services.
The United States plays a dominant role in the biologics contract development market, driven by its advanced healthcare system, leading pharmaceutical companies, and cutting-edge research institutions. The FDA provides a well-established regulatory framework that ensures the safety and efficacy of biological products, fostering confidence in the market. The U.S. faces a high prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, propelling the demand for biologic treatments. Additionally, the country is a global leader in biotechnology and pharmaceutical innovation, with substantial investments in personalized medicine, gene therapies, and monoclonal antibodies. The growing trend of outsourcing biologic development and manufacturing to contract development organizations (CDOs) enables biopharma companies to reduce costs and focus on innovation.
Moreover, the U.S. government\'s support for research funding and regulatory incentives strengthens the market landscape. With an increasing emphasis on precision medicine, the biologics contract development market in the U.S. is poised for continued growth, maintaining its strong trajectory in the global market.
Biologics Contract Development Market- Competitive Landscape:
The competitive landscape of the biologics contract development market is characterized by several key players who focus on advanced technologies, regulatory compliance, and cost-effective solutions. Leading companies such as Lonza Group, WuXi AppTec, and Samsung Biologics dominate the market with their comprehensive service offerings in biologic drug development, including process development, manufacturing, and clinical trial support. For instance, Lonza Group provides state-of-the-art facilities and expertise in large-scale biologics production, particularly for monoclonal antibodies. WuXi AppTec is known for its integrated services across drug discovery, development, and manufacturing, with a strong emphasis on personalized medicine. Samsung Biologics combines cutting-edge biomanufacturing capabilities with a focus on operational efficiency and strict regulatory adherence. These companies have established strong relationships with pharmaceutical firms and biotechnology companies, positioning themselves as preferred partners in biologic development. Their ability to scale production, ensure quality control, and adapt to evolving regulatory standards continues to strengthen their competitive edge in the market.
Recent Developments:
v February 2023: Lonza expanded its presence in the U.S. with the opening of a new laboratory focused on developing drugs in the early stages of clinical trials. This expansion enhances Lonza\'s ability to support drug development from discovery through to clinical stages, further solidifying its position in the biologics contract development space.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
Ø Lonza Group
Ø WuXi AppTec
Ø Samsung Biologics
Ø Catalent
Ø Boehringer Ingelheim
Ø AbbVie
Ø Fujifilm Diosynth Biotechnologies
Ø CordenPharma
Ø Samsung Biologics
Ø Patheon (Thermo Fisher Scientific)
Ø Merck KGaA
Ø KBI Biopharma
Ø Recipharm
Ø Minaris Regenerative Medicine
Ø Syngene International
Ø Rentschler Biopharma
Ø Almac Group
Ø Emergent BioSolutions
GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY SERVICE TYPE- MARKET ANALYSIS, 2019 - 2032
Ø Contract Research
Ø Contract Manufacturing
Ø Contract Testing
GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY BIOLOGICS TYPE- MARKET ANALYSIS, 2019 - 2032
Ø Monoclonal Antibodies
Ø Vaccines
Ø Gene Therapies
Ø Recombinant Proteins
GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032
Ø Pharmaceutical Companies
Ø Biotechnology Companies
Ø Academic & Research Institutions
GLOBAL BIOLOGICS CONTRACT DEVELOPMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
Ø North America
o U.S.
o Canada
Ø Europe
o Germany
o UK
o France
o Italy
o Spain
o The Netherlands
o Sweden
o Russia
o Poland
o Rest of Europe
Ø Asia Pacific
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Thailand
o Philippines
o Rest of APAC
Ø Latin America
o Brazil
o Mexico
o Argentina
o Colombia
o Rest of LATAM
Ø The Middle East and Africa
o Saudi Arabia
o UAE
o Israel
o Turkey
o Algeria
o Egypt
o Rest of MEA
TABLE OF CONTENT
1. Biologics Contract Development Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Biologics Contract Development Market Snippet by Service Type
2.1.2. Biologics Contract Development Market Snippet by Biologics Type
2.1.3. Biologics Contract Development Market Snippet by End-User
2.1.4. Biologics Contract Development Market Snippet by Country
2.1.5. Biologics Contract Development Market Snippet by Region
2.2. Competitive Insights
3. Biologics Contract Development Key Market Trends
3.1. Biologics Contract Development Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Biologics Contract Development Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Biologics Contract Development Market Opportunities
3.4. Biologics Contract Development Market Future Trends
4. Biologics Contract Development Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Biologics Contract Development Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Biologics Contract Development Market Landscape
6.1. Biologics Contract Development Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Biologics Contract Development Market – By Service Type
7.1. Overview
7.1.1. Segment Share Analysis, By Service Type, 2024 & 2032 (%)
7.1.2. Contract Research
7.1.3. Contract Manufacturing
7.1.4. Contract Testing
Biologics Contract Development Market – By Biologics Type
7.2. Overview
7.2.1. Segment Share Analysis, By Biologics Type, 2024 & 2032 (%)
7.2.2. Monoclonal Antibodies
7.2.3. Vaccines
7.2.4. Gene Therapies
7.2.5. Recombinant Proteins
8. Biologics Contract Development Market – By End-User
8.1. Overview
8.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
8.1.2. Pharmaceutical Companies
8.1.3. Biotechnology Companies
8.1.4. Academic & Research Institutions
9. Biologics Contract Development Market– By Geography
9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
9.2. North America
9.2.1. Overview
9.2.2. Biologics Contract Development Key Manufacturers in North America
9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.2.4. North America Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.2.5. North America Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.2.6. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.2.7. The U.S.
9.2.7.1. Overview
9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.7.3. U.S. Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.2.7.4. U.S. Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.2.7.5. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.2.8. Canada
9.2.8.1. Overview
9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.2.8.3. Canada Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.2.8.4. Canada Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.2.8.5. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3. Europe
9.3.1. Overview
9.3.2. Biologics Contract Development Key Manufacturers in Europe
9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.3.4. Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.5. Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.6. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.7. Germany
9.3.7.1. Overview
9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.7.3. Germany Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.7.4. Germany Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.7.5. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.8. UK
9.3.8.1. Overview
9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.8.3. UK Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.8.4. UK Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.8.5. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.9. France
9.3.9.1. Overview
9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.9.3. France Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.9.4. France Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.9.5. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.10. Italy
9.3.10.1. Overview
9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.10.3. Italy Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.10.4. Italy Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.10.5. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.11. Spain
9.3.11.1. Overview
9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.11.3. Spain Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.11.4. Spain Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.11.5. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.12. The Netherlands
9.3.12.1. Overview
9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.12.3. The Netherlands Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.12.4. The Netherlands Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.12.5. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.13. Sweden
9.3.13.1. Overview
9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.13.3. Sweden Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.13.4. Sweden Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.13.5. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.14. Russia
9.3.14.1. Overview
9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.14.3. Russia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.14.4. Russia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.14.5. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.15. Poland
9.3.15.1. Overview
9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.15.3. Poland Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.15.4. Poland Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.15.5. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.3.16. Rest of Europe
9.3.16.1. Overview
9.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.3.16.3. Rest of the Europe Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.3.16.4. Rest of the Europe Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.3.16.5. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4. Asia Pacific (APAC)
9.4.1. Overview
9.4.2. Biologics Contract Development Key Manufacturers in Asia Pacific
9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.4.4. APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.5. APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.6. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.7. China
9.4.7.1. Overview
9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.7.3. China Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.7.4. China Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.7.5. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.8. India
9.4.8.1. Overview
9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.8.3. India Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.8.4. India Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.8.5. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.9. Japan
9.4.9.1. Overview
9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.9.3. Japan Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.9.4. Japan Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.9.5. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.10. South Korea
9.4.10.1. Overview
9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.10.3. South Korea Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.10.4. South Korea Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.10.5. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.11. Australia
9.4.11.1. Overview
9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.11.3. Australia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.11.4. Australia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.11.5. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.12. Indonesia
9.4.12.1. Overview
9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.12.3. Indonesia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.12.4. Indonesia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.12.5. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.13. Thailand
9.4.13.1. Overview
9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.13.3. Thailand Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.13.4. Thailand Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.13.5. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.14. Philippines
9.4.14.1. Overview
9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.14.3. Philippines Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.14.4. Philippines Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.14.5. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.4.15. Rest of APAC
9.4.15.1. Overview
9.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.4.15.3. Rest of APAC Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.4.15.4. Rest of APAC Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.4.15.5. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5. Latin America (LATAM)
9.5.1. Overview
9.5.2. Biologics Contract Development Key Manufacturers in Latin America
9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.5.4. LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.5.5. LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.5.6. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5.7. Brazil
9.5.7.1. Overview
9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.7.3. Brazil Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.5.7.4. Brazil Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.5.7.5. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5.8. Mexico
9.5.8.1. Overview
9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.8.3. Mexico Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.5.8.4. Mexico Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.5.8.5. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5.9. Argentina
9.5.9.1. Overview
9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.9.3. Argentina Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.5.9.4. Argentina Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.5.9.5. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5.10. Colombia
9.5.10.1. Overview
9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.10.3. Colombia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.5.10.4. Colombia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.5.10.5. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.5.11. Rest of LATAM
9.5.11.1. Overview
9.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.5.11.3. Rest of LATAM Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.5.11.4. Rest of LATAM Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.5.11.5. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6. Middle East and Africa (MEA)
9.6.1. Overview
9.6.2. Biologics Contract Development Key Manufacturers in the Middle East and Africa
9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
9.6.4. MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.5. MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.6. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.7. Saudi Arabia
9.6.7.1. Overview
9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.7.3. Saudi Arabia Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.7.4. Saudi Arabia Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.7.5. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.8. UAE
9.6.8.1. Overview
9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.8.3. UAE Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.8.4. UAE Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.8.5. UAE Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.9. Israel
9.6.9.1. Overview
9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.9.3. Israel Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.9.4. Israel Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.9.5. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.10. Turkey
9.6.10.1. Overview
9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.10.3. Turkey Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.10.4. Turkey Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.10.5. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.11. Algeria
9.6.11.1. Overview
9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.11.3. Algeria Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.11.4. Algeria Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.11.5. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.12. Egypt
9.6.12.1. Overview
9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.12.3. Egypt Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.12.4. Egypt Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.12.5. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
9.6.13. Rest of MEA
9.6.13.1. Overview
9.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
9.6.13.3. Rest of MEA Market Size and Forecast, By Service Type, 2019 - 2032 (US$ Million)
9.6.13.4. Rest of MEA Market Size and Forecast, By Biologics Type, 2019 - 2032 (US$ Million)
9.6.13.5. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
10. Key Vendor Analysis- Biologics Contract Development Industry
10.1. Competitive Dashboard
10.1.1. Competitive Benchmarking
10.1.2. Competitive Positioning
10.2. Company Profiles
10.2.1. Lonza Group
10.2.2. WuXi AppTec
10.2.3. Samsung Biologics
10.2.4. Catalent
10.2.5. Boehringer Ingelheim
10.2.6. AbbVie
10.2.7. Fujifilm Diosynth Biotechnologies
10.2.8. CordenPharma
10.2.9. Samsung Biologics
10.2.10. Patheon (Thermo Fisher Scientific)
10.2.11. Merck KGaA
10.2.12. KBI Biopharma
10.2.13. Recipharm
10.2.14. Minaris Regenerative Medicine
10.2.15. Syngene International
10.2.16. Rentschler Biopharma
10.2.17. Almac Group
10.2.18. Emergent BioSolutions
11. 360 Degree AnalystView
12. Appendix
12.1. Research Methodology
12.2. References
12.3. Abbreviations
12.4. Disclaimer
12.5. Contact Us
